Obesity, Diabetes mellitus type II research hub

A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus

This study is testing a new medicine, BI 456906, for people who are overweight or have obesity and type 2 diabetes. We want to see if it helps with weight loss and is safe to use over about 1.5 years, compared to a dummy medicine.